DBV.F DBV Technologies S.A.

Healthcare Biotechnology Frankfurt Exchange
2.06 EUR
Close of Nov 11, 2026
1.50 4.75
Market cap
EUR 647M
P/E
-
P/B
4.58x
ROE
-145.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DBV.F undervalued?

Graham number

The Graham number of DBV Technologies S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DBV Technologies S.A. fundamental analysis

No fundamental analysis for DBV Technologies S.A. yet.

DBV Technologies S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.…

Full company profile